(Albany,US) DelveInsight has launched a new report on “Ataxia Telangiectasia (AT) – Market Insights, Epidemiology, and Market Forecast-2030″.
DelveInsight’s “Ataxia Telangiectasia (AT) – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Ataxia Telangiectasia (AT) , historical and forecasted epidemiology as well as the Ataxia Telangiectasia (AT) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
Request for Free Sample Report: https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market
Scope of the Report
Ataxia-Telangiectasia (A-T) is a rare inherited disorder that affects the nervous system, immune system, and other body systems. This disorder is characterized by progressive difficulty in coordinating movements (ataxia) beginning in early childhood, usually before age 5. Affected individuals tend to have high amount of a protein called alpha-fetoprotein (AFP) in their blood. It is categorized as Typical (childhood onset) and Atypical (adult onset).
Mutations in the Ataxia-Telangiectasia mutated kinase (ATM) gene cause ataxia-telangiectasia. The ATM gene provides instructions for making a protein that helps control cell division and is involved in DNA repair. This protein plays an important role in the normal development and activity of several body systems, including the nervous system and immune system. Without this protein, cells become unstable and eventually die. Cells in the part of the brain involved in coordinating movements (the cerebellum) are particularly affected by loss of the ATM protein.
Affected children typically develop difficulty in walking, problems with balance and hand coordination, involuntary jerking movements (chorea), muscle twitches (myoclonus), and disturbances in nerve function (neuropathy). Its prevalence is same in both male and female.
Some of the Companies Covered:
Drugs Covered:
Table of Contents:
1. Key Insights
2. Executive Summary of Ataxia Telangiectasia (AT)
3. Competitive Intelligence Analysis for Ataxia Telangiectasia (AT)
4. Ataxia Telangiectasia (AT): Market Overview at a Glance
5. Ataxia Telangiectasia (AT): Disease Background and Overview
6. Patient Journey
7. Ataxia Telangiectasia (AT) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Ataxia Telangiectasia (AT) Treatment
11. Marketed Products
12. Emerging Therapies
13. Ataxia Telangiectasia (AT) : Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Ataxia Telangiectasia (AT)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/ataxia-telangiectasia-at-market